|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we found that the mechanism by which DAP elicited anti-osteoporotic effects was mediated by up-regulation of VEGF and OPG, but down-regulation of RANK and RANKL in both protein and mRNA expression in OVX rats, as well as the activation of PI3K/Akt/eNOS signaling pathway, indicating that DAP can be clinically used as a potential alternative medicine for the prevention and treatment of postmenopausal osteoporosis.
|
30735778 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pulsed electromagnetic fields modulate bone metabolism via RANKL/OPG and Wnt/β-catenin pathways in women with postmenopausal osteoporosis: A pilot study.
|
30010081 |
2018 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rebalancing of the RANKL/OPG system seems to be an effective treatment strategy in postmenopausal osteoporosis.
|
30195781 |
2018 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG) is implicated in the pathogenesis of postmenopausal osteoporosis, and other metabolic bone diseases caused by estrogen deficiency.
|
28260003 |
2017 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the study, we first assessed the relationship between OPG variants and BMD or osteoporosis fractures in our sample size (227 subjects with postmenopausal osteoporosis and 189 controls), and then performed a systematic meta-analysis.
|
28496203 |
2017 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a subgroup analyses, OPG T950C polymorphism was significantly associated with the osteoporosis risk in South China (CC+TC vs. TT: OR = 1.34, 95% CI = 1.17-1.54; CC vs. TC+TT: OR = 0.79, 95% CI = 0.69-0.95) and for studies that included postmenopausal osteoporosis (CC vs. TC+TT: OR = 0.78, 95% CI = 0.64-0.94) or hospital-based controls (CC vs. TC+TT: OR = 0.81, 95% CI = 0.68-0.96).
|
29253005 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis.
|
28367895 |
2017 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population.
|
28488893 |
2017 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
OPG 1181G/C and OPG -163A/G polymorphisms have been associated not only with body weight and birth weight, but also with reduced bone density and an increased risk of postmenopausal osteoporosis.
|
26202809 |
2015 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between single nucleotide polymorphisms of the osteoprotegerin gene and postmenopausal osteoporosis in Chinese women.
|
24065669 |
2013 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
|
23543663 |
2013 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urinary excretion of GGT, corrected for creatinine, was found to be increased in osteoprotegerin (OPG)-deficient osteoporotic mice as well as in patients with postmenopausal osteoporosis (67-83 years of age); in both cases the urinary level decreased after treatment of patients or mice with alendronate, a selective inhibitor of bone resorption, concomitantly with a reduction in DPD and NTX.
|
16942925 |
2006 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results indicate the possible role of TNFRSF11B gene variants in postmenopausal bone loss in women in Malta.
|
16343827 |
2006 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis.
|
12213850 |
2002 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
LHGDN |
Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers.
|
12564836 |
2002 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis.
|
12213850 |
2002 |